Eiko Lifesciences shines on getting nod to acquire 51% stake in SSM Formulations
Eiko Lifesciences is currently trading at Rs. 55.39, up by 2.21 points or 4.16% from its previous closing of Rs. 53.18 on the BSE.
The scrip opened at Rs. 53.71 and has touched a high and low of Rs. 59.00 and Rs. 53.18 respectively. So far 8273 shares were traded on the counter.
The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 74.88 on 20-Dec-2024 and a 52 week low of Rs. 42.00 on 04-Mar-2025.
Last one week high and low of the scrip stood at Rs. 54.80 and Rs. 48.00 respectively. The current market cap of the company is Rs. 74.78 crore.
The promoters holding in the company stood at 37.17%, while Non-Institutions held 62.83% stake in the company.
Eiko Lifesciences has secured approval to acquire 51% equity shares of M/s SSM Formulations, a company operating in business of Pharmaceuticals. The Board of Directors of the company in their meeting held on December 11, 2025 have approved the same. The board has approved the acquisition of 71,71,950 shares of SSM Formulations for a consideration of Rs 18 crore. Post acquisition, SSM Formulations will become a subsidiary of the company.
The acquisition constitutes a strategic forward integration move into pharmaceutical formulations, aimed at diversifying the product portfolio and capturing higher value across the pharmaceutical supply chain. It will consolidate company’s market position in specialty chemicals, pharmaceutical intermediates and APIs, while expanding the existing API portfolio and providing access to new niche molecules and client segments. The transaction is expected to generate operational synergies and economies of scale, and the target entity’s business aligns directly with the Company’s core line of activity.
Eiko Lifesciences is a leading manufacturer, supplier and exporter of Specialty Chemicals and Pharma Intermediates in India and Globally.
